Pruritus Therapeutics MarketSize and Trends

Global Pruritus Therapeutics Market – Dynamics

The increase in the number of cases of dermatitis and allergic diseases is expected to propel the growth of global pruritus therapeutics market. For instance, according to the article published in the Indian Journal of Dermatology in 2020, dermatitis was the most common subgroup of hypersensitivity diseases, accounting for 24.5% of all cases of allergic skin disorders. Contact dermatitis (17.54% of the total) was found to be the most commonly detected skin disease in the dermatitis group of diseases.

Moreover, according to European Academy of Allergy and Clinical Immunology, 2016, over 150 million Europeans suffer from chronic allergic diseases, and it is estimated that half of the European Union (EU) population will be affected with chronic allergy disorders by 2025.

The increasing product launches and approvals is expected to boost global pruritus therapeutics market growth. For instance, on May 26, 2020, Sanofi, a global biopharmaceutical company dedicated to human health, announced that the U.S. Food and Drug Administration (FDA) has approved its Dupixent (dupilumab) for children between 6 to 11 years with moderate-to-severe atopic dermatitis (eczema) with pruritus as one of its major symptom. This disease in children is not adequately controlled by topical prescription therapies or those therapies that are contraindicated. Dupixent is the only biologic medicine approved for this patient population in treating eczema with pruritus.

Furthermore, rising mergers, agreements, and acquisitions by market players are expected to propel the global pruritus therapeutics market over the forecast period. For instance, on August 24, 2020, MC2 Therapeutics, a pharmaceutical company that develops topical therapies, announced a collaboration agreement with EPI Health, LLC to commercialize WYNZORA Cream in the U.S. EPI Health is a leading pharmaceutical company in dermatology community. WYNZORA Cream was approved by the U.S. Food and Drug Administration (FDA) on July 20, 2020) for the topical treatment of plaque psoriasis, a common cause of psoriasis itching (pruritus) in adults. These factors are expected to support global pruritus therapeutics market growth over the forecast period.

Global Pruritus Therapeutics Market – Regional Insights

Among regions, North America is expected to account for the largest share in global pruritus therapeutics market over the forecast period, owing to the approval of treatments from regulatory authorities for treatment of pruritus. For instance, on March 8, 2021, the U.S. Food and Drugs Administration (FDA) accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The Prescription Drug User Fee Act (PDUFA) target action date for KORSUVA is August 23, 2021. KORSUVA is marketed by Vifor Pharma, a global pharmaceutical company, which develops products for precision patient care and Cara Therapeutics, Inc., a clinical stage biopharmaceutical company focused on producing new chemical entities to alleviate pruritus.

Moreover, due to rise in agreements and sales partnerships within market players, Europe may witness a lucrative growth in global pruritus therapeutics market over the forecast period. For instance, on February 17, 2021, Almirall S.A., a global biopharmaceutical company, and MC2 Therapeutics, a commercial stage pharmaceutical company, which develops topical therapies for autoimmune and chronic inflammatory conditions, confirmed that MC2 Therapeutics granted Almirall exclusive European rights to commercialize WYNZORA Cream for the treatment of plaque psoriasis, a common cause of psoriasis itching (pruritus) in adults. These factors are expected to support global pruritus therapeutics market growth over the forecast period.